Skip to main content
    S

    Supernus Pharmaceuticals, Inc. (SUPN)

    Official site

    HEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ

    $28.83
    -0.89 (-2.99%)

    Market Cap: $1.52B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Supernus Pharmaceuticals, Inc. (SUPN) P/E Ratio & Valuation History

    Updated Nov 17, 2026. Multiples are computed from end-of-day prices, company filings and consensus analyst estimates.

    Supernus Pharmaceuticals (SUPN) trades at 12.7x trailing earnings and 2.0x sales. Its P/E of 12.7x is below its 5-year median of 17.4x. Its forward P/E is 20.2x. The median P/E across 11 similar companies is 10.7x.

    Current Multiples

    Its forward P/E is above its trailing P/E, which implies earnings per share about 37.1% lower over the next year. Its free cash flow yield is 1.1%.

    MultipleValue
    P/E (trailing)12.7x
    Forward P/E20.2x
    Price to sales2.0x
    Price to book1.6x
    Price to FCF89.1x
    EV/FCF79.5x
    PEG1.5
    FCF yield1.1%
    As of Nov 17, 2026

    Historical Medians

    Against its 10-year medians, its P/E is 76.9% below 54.9x, its P/S is 84.3% below 12.7x and its P/B is 82.2% below 9.0x.

    MultipleCurrent5-year median10-year median
    P/E12.7x17.4x54.9x
    P/S2.0x3.0x12.7x
    P/B1.6x2.1x9.0x
    Medians of month-end values through Oct 2026: 60 months (5-year) and 120 months (10-year).

    Valuation History

    Over the 10 year ends shown, its P/E ranged from 12.6x in 2023 to 158.1x in 2017.

    Year endPriceP/EP/SP/B
    2025$49.7017.5x3.9x2.7x
    2024$36.1614.1x3.0x2.0x
    2023$28.9412.6x2.6x1.7x
    2022$35.6723.5x3.0x2.5x
    2021$145.80148.8x13.4x9.5x
    2020$125.8053.3x12.8x9.1x
    2019$118.6056.2x15.9x10.7x
    2018$166.1080.6x21.3x19.8x
    2017$199.25158.1x33.9x39.9x
    2016$126.25123.8x15.2x37.8x
    Each year's multiples use the split-adjusted closing price of that year's last trading day over trailing per-share results as reported; periods with losses are left out.

    Frequently Asked Questions About SUPN

    What is SUPN's forward P/E ratio?

    Supernus Pharmaceuticals has a forward P/E ratio of 20.2x.

    Is SUPN stock overvalued?

    Its P/E of 12.7x compares with a median of 10.7x across 11 similar companies.

    What is SUPN's price to sales ratio?

    Supernus Pharmaceuticals has a price to sales ratio of 2.0x.

    What is Supernus Pharmaceuticals's average P/E ratio over 5 years?

    Supernus Pharmaceuticals's median P/E over the last 5 years is 17.4x, from 60 month-end values through Oct 2026.

    What is SUPN's PEG ratio?

    Supernus Pharmaceuticals has a PEG ratio of 1.5.